Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL2295611 | 1.00 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1SLC7A5CYP2D6 | |
| Phenazine SCHEMBL28369786 | 0.89 | MAPK1 (0.46) | SLC1A3SLC1A2SLC1A1SLC7A5CYP2D6 | |
| Phenazine SCHEMBL28746322 | 0.89 | MAPK1 (0.46) | SLC1A3SLC1A2SLC1A1SLC7A5CYP2D6 | |
| Threonine SCHEMBL18075540 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1CYP2D6MAPK1 | |
| Alanine SCHEMBL723059 | 0.88 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1CYP2D6MAPK1 | |
| Alanine SCHEMBL3254315 | 0.88 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1CYP2D6MAPK1 | |
| D-Alanine SCHEMBL3725637 | 0.88 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1CYP2D6MAPK1 | |
| Valine SCHEMBL8427947 | 0.85 | SLC7A5 (0.48) | SLC1A3SLC1A2SLC1A1SLC7A5MMP9 | |
| Valine SCHEMBL8427967 | 0.85 | SLC7A5 (0.48) | SLC1A3SLC1A2SLC1A1SLC7A5MMP9 | |
| Valine SCHEMBL8427948 | 0.85 | SLC7A5 (0.48) | SLC1A3SLC1A2SLC1A1SLC7A5MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-107635989-B | Benzimidazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权开发有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| CN-110709071-A | Methods for administering certain VMAT2 inhibitors | 纽罗克里生物科学有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3549939-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| EP-3271349-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| EP-3271349-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146738-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| EP-1747190-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | INKE, S.A. (ES) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005102987-A1 | PROCESS FOR THE PREPARATION OF VALSARTAN AND PRECURSORS THEREOF | INKE, S.A. (ES) | 2005-11-03 | — | — | WO | disclosed |
| EP-0748791-B1 | Valine p-isopropylbenzene sulfonate and a process for purifying valine | AJINOMOTO KK (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0748791-A2 | Valine p-isopropylbenzene sulfonate and a process for purifying valine | Ajinomoto Co., Inc. (JP) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | SLC1A3 3934/4885SLC1A2 4429/4885SLC1A1 3737/4885 |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | SLC1A3 3934/4885SLC1A2 4429/4885SLC1A1 3737/4885 |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | SLC1A3 3934/4885SLC1A2 4429/4885SLC1A1 3737/4885 |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | SLC1A3 3934/4885SLC1A2 4429/4885SLC1A1 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.